InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,461.96
(
0.25%
)
Dow Jones
38,675.68
(
0.00%
)
Brent Oil
83.48
(
0.42%
)
Bitcoin
64,186.24
(
0.29%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

iwfal

Send PM Follow Ignore
Followers 75
Posts 4648
Boards Moderated 0
Alias Born 09/06/2003

iwfal

Member Level

Re: jq1234 post# 180818

Wednesday, 07/30/2014 2:04:43 AM

Wednesday, July 30, 2014 2:04:43 AM

Post# of 251721
SRPT

If you really think not much has learned in the past two years about trial designs from various Ataluren, Drisapersen, eteplirsen trials, well, I don't know what else to say except sorry I waited time. ... Drisapersen ph3 failure changed many things



By focusing on RNA and PTCT I would suggest you are acknowledging not much learned from their own trial per se. I would agree that drafting behind others does work. But it also means their own trials aren't very informative - not awesome for justifying approval.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up